Boosting the body's own defenses against breast cancer
Small molecule enhancers of tumor immunity targeting the LPA5 GPCR
This work looks for new medicines that can help your immune system's T cells fight breast cancer more effectively.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-11144281 on NIH RePORTER |
What this research studies
Our immune system has special cells called CD8 T cells that are designed to kill cancer cells. However, a molecule called LPAR5 can put the brakes on these T cells, making them less effective at fighting tumors. This project aims to find small molecules that can block LPAR5, essentially taking the brakes off the T cells. By doing so, we hope to unleash the full power of your immune system to attack and destroy breast cancer cells.
Who could benefit from this research
Good fit: This foundational research is focused on understanding immune responses in breast cancer, and future clinical applications would target patients with breast cancer.
Not a fit: Patients without breast cancer or those whose cancer does not involve the LPAR5 pathway may not directly benefit from this specific approach.
Why it matters
Potential benefit: If successful, this research could lead to new drug treatments that enhance the body's natural ability to fight breast cancer, potentially improving outcomes for patients.
How similar studies have performed: Other approaches that target immune checkpoints have shown significant success in cancer treatment, suggesting promise for this novel target.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Tigyi, Gabor J — University of Tennessee Health Sci Ctr
- Study coordinator: Tigyi, Gabor J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.